Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone
IMpower-110 (TC1/2/3 or IC1/2/3), 2020
  NCT02409342
RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinium chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 1/2/3)277 / 277some concern
inconclusive
  • inconclusive 17 % decrease in deaths (OS) (PE)
  • suggested 28 % decrease in PFS (extension)
  • suggested 23 % decrease in progression or deaths (PFS)
IMpower-110 (TC3 or IC3), 2020
 
NCT02409342
RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinum chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 3)107 / 98some concern
conclusif
  • demonstrated 41 % decrease in deaths (OS) (PE)
  • suggested 41 % decrease in PFS (extension)
  • suggested 37 % decrease in progression or deaths (PFS)
IMpower-110 (TC2/3 or IC2/3), 2020
 
NCT02409342
RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinium chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC2/3)166 / 162some concern
suggested
  • suggested 28 % decrease in deaths (OS) (PE)
  • suggested 36 % decrease in PFS (extension)
  • suggested 33 % decrease in progression or deaths (PFS)